Full text is available at the source.
Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area
Real-world use of glucagon-like peptide-1 receptor drugs in people with type 2 diabetes in the Mediterranean region
AI simplified
Abstract
A total of 4242 patients with type 2 diabetes initiated glucagon-like peptide-1 receptor agonists, showing a mean HbA1c decrease from 8.8% to 7.7% at 6-12 months.
- A 1% reduction in HbA1c was achieved by 47.2% of patients.
- Patients experienced an average body weight loss of 3.6 kg over the same period.
- Sixty percent of patients successfully reduced both HbA1c and body weight.
- Independent factors linked to achieving a ≥1% HbA1c reduction included baseline HbA1c, age, duration of diabetes, and insulin treatment.
- Patients prescribed liraglutide experienced greater reductions in HbA1c and body weight compared to those on exenatide or lixisenatide.
AI simplified